| |
Newsroom /
Business
/
Business
/
Pharmaceutical Mergers and Acquisitions
Pharmaceutical Mergers and Acquisitions
Pharmaceutical Mergers and Acquisitions guides you to build an M&A plan that focuses on key goals, avoids costly mistakes, and realizes deal potential as quickly as possible. CEI designed this study to identify the primary drivers of M&A activity. Through the input of pharma industry leaders, our study provides solutions to the greatest M&A pitfalls and gives clear, detailed insight of trends in pharmaceutical deals. The result: a roadmap to the M&A landscape.
Navi Mumbai,
Maharashtra,
India
(prbd.net)
01/11/2010
Ensure merger and acquisition success - at any point in the M&A process
Pharmaceutical Mergers and Acquisitions guides you to build an M&A plan that focuses on key goals, avoids costly mistakes, and realizes deal potential as quickly as possible. CEI designed this study to identify the primary drivers of M&A activity. Through the input of pharma industry leaders, our study provides solutions to the greatest M&A pitfalls and gives clear, detailed insight of trends in pharmaceutical deals. The result: a roadmap to the M&A landscape.
The past year has been marked by heightened M&A activity among companies of all sizes. Small companies are increasingly investing in large-molecule products that are expensive to produce and test in clinical trials - but in this tough economic climate, they face diminishing capital and the threat of closing. To continue their work on time-sensitive compounds, they are exploring the possibility of a company sale. On the other hand, for those companies with cash, this situation presents an opportunity to acquire attractive compounds and technology platforms at a discount.
Timelines, rankings, strategies, and deal profiles will allow you to maximize the benefits and growth opportunities of a deal:
Understand the M&A environment
Learn what is driving the acquisition strategies of top companies - and how other organizations are seeking suitors for their own sales.
Build a competitive deal-making process
• Target the right deals with an M&A task force
• Implement a timeline that works for both sides
• Track different types of financing across deals brokered by companies of different sizes
Complete the integration as soon as possible -- and boost productivity
• Build an integration timeline
• Clarify roles and responsibilities in the new organization
• Reduce the impact of attrition
Learn from the recent past
We've vetted the top 75 deals of 2009 to determine purchasing trends, including:
• Price/pipeline ratios
• Financing options
• Deal motivators
Look into the future of M&A
Gather perspectives and predictions on future deals from the managers who execute them.
Compare your deal to others
• Use the deal profiles to compare metrics for 19 different deals
• Explore deal size, functional involvement in deal-making, timelines, challenges and employee retention
Excerpts
• Sample Content from the Report
The following excerpt is taken from Chapter 1, "Deal Background." The chapter discusses some of the key motives of profiled companies and the logistics of M&A purchases. It sets the stage for the entire report and places profiled deals in context.
Specific Deal Details
Figure 1.10 [data appear in full report] lists the individual values of the deals used as examples by survey respondents and interviewees when they discussed M&A activity. Teams report a wide array of deal prices, with the average value landing at $188 million. Among these acquisitions, 41% were complete between four and six months of initiation (Figure 1.11) [data appear in full report]. Organizations push deals through as quickly as possible to save money and to get the ball rolling on operational and personnel integration.
Though no formula exists for deal standardization, organizations do have a starting point of interest for acquisition targets. An interviewed executive from Deal 7 explains that purchasers lower overall risks taken in M&A when they seek products in Phase 2 clinical trials and beyond. Products in Phase 2 typically carry a higher price, but at that point, organizations can be assured that the product has proof of concept.
The following excerpt is taken from Chapter 3, "Resolving Integration Challenges." Metrics identify the top post-merger challenges. Interviewed participants provide recommendations on how to overcome them.
Recruit Committed Leadership for Merged Company
Deal 2 suffered another mistake that led to terrible results for the acquired employees. The venture capital firm funding both companies wanted to remove a poorly performing CEO from the larger company, so it solicited and received a commitment from the CEO of the smaller company to perform this function for the combined company. Unfortunately, the CEO only committed to run the company until the firm could find a replacement - and only on a part-time basis. He had little desire to actively pursue true integration of the two companies.
As a result, the employees from his own company were sidelined, and the organizational deficits of the larger company remained unaddressed. Moreover, finding the replacement took longer than anticipated. Before a replacement could be found, all projects from the smaller company had been cancelled, and all employees who were not contractually guaranteed a job were fired or quit.
For more information kindly visit
http://www.bharatbook.com/detail.asp?id=125094&rt=Pharmaceutical-Mergers-and-Acquisitions.html
OR Contact us at
Bharat Book Bureau
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
About
Bharat Book Bureau is the leading business information aggregator providing market research reports and online databases. Bharatbook is also into the business of marketing conferences worldwide and undertakes custom research.
Category :
Business:Business
Subscribe to
Business Keywords :
Demand Forecast, Market, Market Forecast, Market Growth, Market Leaders, Market Report, Market Share, Market Size, Mergers & Acquisitions, Report, Res
|